Innovative blood tests for early detection and accurate management of cancer

Prostate Cancer Diagnosis

Are you over 50 with a slightly elevated PSA that suggest for a prostate biopsy? Thanks to BIOPROGNOS' OncoPROSTATE Dx test, you can confirm or discard the presence of a Prostate Cancer with a simple analysis of blood and urine.

Non-Invasive Cancer Diagnosis Revolution

BIOPROGNOS launches the first non-invasive tests ―based on a simple blood test―, to help in the diagnosis of Breast, Lung, Ovarian and Prostate cancers, as well as in Cancer of Unknown Primary.

Prostate Cancer Diagnosis

Breast Cancer Diagnosis

Are you a women more than 40 with a suspicious mass in the breast that suggest for a biopsy? The new BIOPROGNOS' OncoBREAST Dx test can save up to 90% of unnecessary biopsies.

Prostate Cancer Diagnosis

Lung Cancer Diagnosis

Are you a smoker more than 55 with a suspicious mass in the lungs that suggest for a biopsy? Thanks to OncoLUNG Dx test, you can rule out malignancy to avoid unnecessary biopsies.

Prostate Cancer Diagnosis

Ovarian Cancer Diagnosis

Do you have abdominal pain or your Gynecologist has found a suspicious adnexal mass? Thanks to OncoOVARIAN Dx test, you can confirm or discard an ovarian malignancy with a simple blood test.

Prostate Cancer Diagnosis

Multiple Biomarkers Disease Activity Algorithms (MBDAAs)

Biomarkers are making their way into investigation and are producing an enormous amount of information: With the rapid advances in genomic and proteomic technology, the discovery of useful biomarkers has arisen to unravel the unique signatures of cancer cells, enabling investigators to pose scientific questions and address problems that, until recently, were inconceivable.

This has shifted the focus on biomarker-based disease detection from one biomarker to a panel of biomarkers, for which we develop Multiple Biomarkers Disease Activity Algorithms (MBDAAs) as standard-of-care replacement for diagnosis, confirmatory diagnostic ―as an adjunct to suspicious image procedures findings, in order to reduce the number of unnecessary tissue biopsies that patients have to undergo―, or as complementary criteria.

Available MBDAA Tests

Key Facts

Barcelona Criteria

Big Data Large Trial Studies

Top ROC Curves Performance

AI-Based Machine Learning

Secure Cloud Platform

Proprietary RALD Framework

Benefits

Rational Decision

MBDAAs are tools for effect rational decision making on the health care of patients in a cost-effective manner.

Care Replacement

MBDAAs can replace standard-of-care technologies, complement criteria, as well as act as other tests confirmation.

Non Invasive Solution

MBDAAs can avoid patients from other uncomfortable screening methods, such as colonoscopy or biopsy.

Affordable Alternative

MBDAAs are cheaper than other procedures and, in some cases, the only option if it is not possible to access the tumor.

Accurate Diagnosis

As our MBDAAs work at molecular level (both proteomic and genetic), types and subtypes of disease can be diagnosed accurately.

Best for Early Detection

MBDAAs can show early detection of illness in healthy people before symptoms develop, increasing recovery chance.

Therapy Monitoring

Doctors may use changes in the presence or amount of one or more Tumor Markers to assess how the illness is responding to treatment.

Monitor for Recurrence

Looking for changes in the amount of a Tumor Marker may help as follow-up care plan to detect a recurrence sooner than other methods.